Immunostimulatory oligonucleotide multimers
AssigneeIdera Pharmaceuticals, Inc.
InventorsSudhir Agrawal, Ekambar Kandimalla, Dong Yu
Life of this patent
Estimating the term…
Abstract
The invention provides an immunostimulatory nucleic acid. In certain embodiments according to this aspect of the invention, the sequence of the immunostimulatory oligonucleotide and/or immunomer is at least partially self-complementary.
Claims9
1-21. (canceled)
A method for treating a patient having airway inflammation, allergy, or asthma, such method comprising administering to the patient an immunostimulatory oligonucleotide having the structure 5′-TCG1AACG1TTCG1-X-G1CTTG1CAAG1CT-5′(SEQ ID NO 1), 5′-CTGTCoG2TTCTC-X-CTCTTG2oCTGTC-5′(SEQ ID NO 29), 5′-CTGTCG2TTCTCo-X-oCTCTTG2CTGTC-5′(SEQ ID NO 28), 5′-TCG1AACG1TTCG1-Y-TCTTG2CTGTCT-5′(SEQ ID NOs 22 AND 35), or 5′-TCG1AACG1TTCG1-Y-GACAG1CTGTCT-5′(SEQ ID NOs 32 AND 38);
- wherein X is a glycerol linker, Y is a C3-linker, G1 is 2′-deoxy-7-deazaguanosine, G2 is arabinoguanosine and o is phosphodiester linkage.
A method for preventing airway inflammation, allergy, or asthma, such method comprising administering to a patient an immunostimulatory oligonucleotide having the structure 5′-TCG1AACG1TTCG1-X-G1CTTG1CAAG1CT-5′(SEQ ID NO 1), 5′-CTGTCoG2TTCTC-X-CTCTTG2oCTGTC-5′(SEQ ID NO 29), 5% CTGTCG2TTCTCo-X-oCTCTTG2CTGTC-5′(SEQ ID NO 28), 5′-TCG1AACG1TTCG1-Y-TCTTG2CTGTCT-5′(SEQ ID NOs 22 AND 35), or 5′-TCG1AACG1TTCG1-Y-GACAG1CTGTCT-5′(SEQ ID NOs 32 AND 38);
- wherein X is a glycerol linker, Y is a C3-linker, G1 is 2′-deoxy-7-deazaguanosine, G2 is arabinoguanosine and o is phosphodiester linkage.
A pharmaceutical composition comprising an immunostimulatory oligonucleotide having the structure 5′-TCG1AACG1TTCG1-X-G1CTTG1CAAG1CT-5′(SEQ ID NO 1), 5′-CTGTCoG2TTCTC-X-CTCTTG2oCTGTC-5′(SEQ ID NO 29), 5′-CTGTCG2TTCTCo-X-oCTCTTG2CTGTC-5′(SEQ ID NO 28), 5′-TCG1AACG1TTCG1-Y-TCTTG2CTGTCT-5′(SEQ ID NOs 22 AND 35), or 5′-TCG1AACG1TTCG1-Y-GACAG1CTGTCT-5′(SEQ ID NOs 32 AND 38);
- wherein X is a glycerol linker, Y is a C3-linker, G1 is 2′-deoxy-7-deazaguanosine, G2 is arabinoguanosine and o is phosphodiester linkage.
Dependencies are inferred from the claim text.